Effects of Intravitreal Bevacizumab (Avastin®) Therapy on Retrobulbar Blood Flow Parameters in Patients With Neovascular Age-Related Macular Degeneration

被引:24
|
作者
Mete, Ahmet [1 ]
Saygili, Oguzhan [2 ]
Mete, Alper [2 ]
Bayram, Metin [1 ]
Bekir, Necdet [2 ]
机构
[1] Gaziantep Univ, Sch Med, Dept Radiol, Sahinbey, Gaziantep, Turkey
[2] Gaziantep Univ, Sch Med, Dept Ophtalmol, Sahinbey, Gaziantep, Turkey
关键词
color Doppler imaging; retrobulbar blood flow; neovascular age-related macular degeneration; intravitreal bevacizumab injection; ENDOTHELIAL GROWTH-FACTOR; DOPPLER ULTRASONOGRAPHY; HEMODYNAMICS; ORBIT; EYE; MACULOPATHY; SAFETY; EDEMA;
D O I
10.1002/jcu.20650
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Background. To investigate the effects of intravitreal bevacizumab on retrobulbar circulation in patients with neovascular age-related macular degeneration (AMD). Method. Thirty patients with neovascular age-related macular degeneration were assessed prospectively by both color Doppler imaging and fundus fluorescein angiography. Spectral Doppler analysis allowed the measurement of the maximum velocity (Vmax) and minimum velocity (Vmin) of the central retinal vein (CRV), and peak systolic (PSV), end-diastolic (EDV) velocities of blood flows, and pulsatility index (PI) and resistance index (RI) values in the central retinal artery (CRA), nasal and temporal posterior ciliary arteries (NPCA, TPCA), and ophthalmic artery (OA). The t test for paired samples was used to compare retrobulbar blood flow values before and after intravitreal bevacizumab injection. Result. PSV and EDV of the NPCA and PSV of the TPCA were significantly decreased after intravitreal bevacizumab injection (p < 0.05). There was no statistically significant difference in the other parameters. Conclusion. Our results suggest that intravitreal bevacizumab therapy has a measurable effect on retrobulbar blood flow. (C) 2009 Wiley Periodicals, Inc. J Clin Ultrasound 38:66-70, 2010; Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jcu.20650
引用
收藏
页码:66 / 70
页数:5
相关论文
共 50 条
  • [1] Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    Avery, RL
    Pieramici, DJ
    Rabena, MD
    Castellarin, AA
    Nasir, MA
    Giust, MJ
    OPHTHALMOLOGY, 2006, 113 (03) : 363 - 372
  • [2] Short-term effects of intravitreal bevacizumab (Avastin®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration
    Toklu, Yasin
    Cakmak, Hasan Basri
    Raza, Sabri
    Anayol, Alpaslan
    Asik, Elif
    Simsek, Saban
    ACTA OPHTHALMOLOGICA, 2011, 89 (01) : E41 - E45
  • [3] Early effects of systemic and intravitreal bevacizumab (Avastin®) therapy for neovascular age-related macular degeneration
    Geitzenauer, W.
    Michels, S.
    Prager, F.
    Kornek, G.
    Vormittag, L.
    Rosenfeld, P.
    Schmidt-Erfurth, U.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2006, 223 (10) : 822 - 827
  • [4] Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration
    Levy J.
    Shneck M.
    Rosen S.
    Klemperer I.
    Rand D.
    Weinstein O.
    Pitchkhadze A.
    Belfair N.
    Lifshitz T.
    International Ophthalmology, 2009, 29 (5) : 349 - 357
  • [5] Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration
    Emerson, M. Vaughn
    Lauer, Andreas K.
    Flaxel, Christina J.
    Wilson, David J.
    Francis, Peter J.
    Stout, J. Timothy
    Emerson, Geoffrey G.
    Schlesinger, Thomas K.
    Nolte, Susan K.
    Klein, Michael L.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (04): : 439 - 444
  • [6] Systemic and intravitreal Bevacizumab (Avastin®) in neovascular age-related macular degeneration
    Michels, S.
    Prager, F.
    Geitzenauer, W.
    Lackner, B.
    Sacu, S.
    Weigert, G.
    Kriechbaum, K.
    Polak, K.
    Georgopoulos, M.
    Schmidt-Erfurth, U.
    SPEKTRUM DER AUGENHEILKUNDE, 2007, 21 (03) : 154 - 159
  • [7] Intravitreal bevacizumab (avastin) in treatment of neovascular age-related macular degeneration
    Lazic, Ratimir
    Gabric, Nikica
    Dekaris, Iva
    Saric, Borna
    Gavric, Morena
    COLLEGIUM ANTROPOLOGICUM, 2007, 31 : 77 - 81
  • [8] Efficacy of intravitreal bevacizumab (Avastin®) therapy for early and advanced neovascular age-related macular degeneration
    Krebs, Ilse
    Lie, Shilla
    Stolba, Ulrike
    Zeiler, Florian
    Felke, Stefan
    Binder, Susanne
    ACTA OPHTHALMOLOGICA, 2009, 87 (06) : 611 - 617
  • [9] Intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration in treatment-naive patients
    Pedersen, Karen Bjerg
    Sjolie, Anne Katrin
    Moller, Flemming
    ACTA OPHTHALMOLOGICA, 2009, 87 (07) : 714 - 719
  • [10] EFFECT OF INTRAVITREAL BEVACIZUMAB ON RETROBULBAR BLOOD FLOW IN INJECTED AND UNINJECTED FELLOW EYES OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Hosseini, Hamid
    Lotfi, Mehrzad
    Esfahani, Mina Heidari
    Nassiri, Nariman
    Khalili, Mohammad Reza
    Razeghinejad, Mohammad Reza
    Nouri-Mahdavi, Kouros
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (05): : 967 - 971